Acerus files a new drug submission for Gynoflor in Canada

Acerus Pharmaceuticals

1 March 2017 - Acerus Pharmaceuticals today announced that it has filed a new drug submission for Gynoflor with Health Canada. 

Gynoflor is an ultra-low dose oestrogen (oestriol) and probiotic (Lactobacillus acidophilus) combination vaginal tablet used for the treatment of symptoms of vaginal atrophy, for the restoration of vaginal flora following the use of anti-infectives and for the treatment of certain vaginal infections. In the submission filed today, Acerus is seeking approval from Health Canada for similar indications.

Read Acerus Pharmaceuticals press release

Michael Wonder

Posted by:

Michael Wonder